<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="626">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>12/10/2005</approvaldate>
  <actrnumber>ACTRN12605000630617</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of anti-coagultion, lipolytic and anti-inflammatory phytotherapeutic agents for the treatment of osteoarthritis</studytitle>
    <scientifictitle>Efficacy of anti-coagultion, lipolytic and anti-inflammatory phytotherapeutic agents for the treatment of osteoarthritis</scientifictitle>
    <utrn />
    <trialacronym>BR95628</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Active (400mg Garlic, 40mg Ginkgo and 250mg Devils Claw) one tablet three time daily, for 12 weeks.</interventions>
    <comparator>Placebo </comparator>
    <control>Placebo</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in WOMAC score from baseline to 12 weeks of treatment.</outcome>
      <timepoint>At baseline and after 12 weeks of treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The change in laboratory lipid status.</outcome>
      <timepoint>From baseline to endpoint (12 weeks of treatment).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The change in laboratory coagulation status.</outcome>
      <timepoint>From baseline to endpoint (12 weeks of treatment).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects with a diagnosis of painful OA of the hip or knee, with or without other joint involvment, as defined by:i) hip or knee pain while standing, walking and/or in motion of at least 3 months duration, and ii) evidence of one or more of the following features in an X-ray picture taken in the past 6 months: osteophytes, cysts or joint space narrowingSubjects with profiles defined by (Triglycerides &gt; 1mmol/L and (ECLT (euglobulin clot lysis time) &gt;190min or Cholesterol &gt;5.9mmol/L)) or (Diastolic blood pressure &gt;85mmHg and &lt;110mmHg).Subjects willing to discontinue their current OA treatment for the study duration, commencing 2 weeks pripor to their first visit (29 weeks).</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of joint replacementSurgery on the knee or hip within the past 12 months or arthroscopy within the past 6 months.Adminstration of any long-acting osteoarthritis therapy in the previous 3 months.Subjects will contra-indications to the study medication or to paracetamol (inlcuding allergies)Subjects with a Diastolic blood pressure of &gt;=100mmHg or systolic blood pressure &gt;= 180mmHg at any stage of the studySubjects on any medication known to interact with anti-hypertensive or lipid lowering drugs or to influence platelet function.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes were held until all subjects had completed the studyand database had been locked. Placebo and active had a similar appearance and weight with the tablets being enterically coated. The placebo tablet were stored in jars that contain dessicant packets that had been laced with garlic oil.</concealment>
    <sequence>The randomisation schedule was provided by the sponsor Blackmores with no restriction method employed</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/04/1996</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Blackmores Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Blackmores Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Na</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Greenslopes Private Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Phillip Cheras</name>
      <address>Australian Centre for Complementary Medicine Education and Research
Mater Health Services
2nd Floor
Community Services Building
39 Annerley Rd
South Brisbane QLD 4101</address>
      <phone>+61 7 38406120</phone>
      <fax />
      <email>p.cheras@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Phillip Cheras</name>
      <address>Australian Centre for Complementary Medicine Education and Research
Mater Health Services
2nd Floor
Community Services Building
39 Annerley Rd
South Brisbane QLD 4101</address>
      <phone>+61 7 38406120</phone>
      <fax />
      <email>p.cheras@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>